The cardiovascular physiology and pharmacology of endothelin-1.
about
Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentanAir Pollution-Induced Vascular Dysfunction: Potential Role of Endothelin-1 (ET-1) SystemEmerging Metabolic Therapies in Pulmonary Arterial Hypertension.Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.The physiological functions of iron regulatory proteins in iron homeostasis - an update.Acute Chagas disease induces cerebral microvasculopathy in miceRole of endothelin-A receptors in optic nerve head red cell flux regulation during isometric exercise in healthy humans.Pivotal role of mouse mast cell protease 4 in the conversion and pressor properties of Big-endothelin-1.Contribution of NADPH oxidase to membrane CD38 internalization and activation in coronary arterial myocytesDistinct ETA receptor binding mode of macitentan as determined by site directed mutagenesisThe COP9 signalosome and vascular function: intriguing possibilities?Dual Endothelin Receptor Blockade Abrogates Right Ventricular Remodeling and Biventricular Fibrosis in Isolated Elevated Right Ventricular AfterloadPathological Importance of the Endothelin-1/ET(B) Receptor System on Vascular DiseasesEpigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer.Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptorDeletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational derepression of HIF2α.Mechanisms of enhanced basal tone of brain parenchymal arterioles during early postischemic reperfusion: role of ET-1-induced peroxynitrite generation.Emerging drugs which target the renin-angiotensin-aldosterone system.Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma.Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.The cardiovascular effects of insulin.The role of endothelin-1 in pulmonary arterial hypertension.Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.Development of macitentan for the treatment of pulmonary arterial hypertension.Endothelial dysfunction and vascular disease - a 30th anniversary update.Molecular mechanisms of atrial fibrosis: implications for the clinic.Endothelin receptor antagonists in sickle cell disease: A promising new therapeutic approach.Lung Circulation.Targeting vascular (endothelial) dysfunction.Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line.Non-Adrenergic, Tamsulosin-Insensitive Smooth Muscle Contraction is Sufficient to Replace α1 -Adrenergic Tension in the Human Prostate.Endothelin-1 in the human myocardium and circulating plasma: evaluation before, during and after correction of aortic stenosis with aortic valve replacement.Cardiopulmonary effects induced by occupational exposure to titanium dioxide nanoparticles.Big endothelin-1 level is a useful marker for predicting the presence of isolated coronary artery ectasia.Human Fibrotic Diseases: Current Challenges in Fibrosis Research.Estimation of Some Oxidative Stress Parameters and Blood Pressure After Administration of Endothelin-1 (ET-1) in Rats.
P2860
Q26851546-9E12F1B7-F55A-427E-B772-82AC808477DCQ28383288-476F30AF-4556-4DCA-B544-1607092E3010Q33608219-41FA22AF-4624-4983-800C-D936226CED93Q33653672-94647EAD-45EC-4C61-8E16-98A9DFFB13A0Q33752116-980CB0CF-6748-451D-82E8-EDB98AF317F4Q33881623-BCBDB48B-1089-4D9C-8D13-F5FCFCA41B6FQ34458787-0E765E2E-0A5A-41C9-88E5-6D5D0AB9D3E0Q34675945-92D1820E-ECB8-40EF-B041-85EECF0E1A2EQ34937098-1E20DFBA-8BBC-4A20-BB29-893203A93263Q35256194-8CA9ADA3-19B4-49FD-9E0D-A8D334899253Q35700589-9406412A-BE33-43B8-9AED-01B389D24245Q35893732-DE7F611F-5169-41B1-8CF6-BDDC4F83A5AAQ36147880-F33EBEB3-142C-4766-9542-7ECE572BF065Q36405934-096B48D3-8873-41E9-9A25-B225F6C30224Q36588721-1BAB6243-1A3F-4633-BFFC-2C62F794870EQ36602744-617CDA46-42AA-429B-A78C-F372C097A411Q37216163-C7B4AA4C-9B51-48F2-8D0C-DFD4C5086C09Q37929786-6537762E-007F-4067-A4BD-8EDA4B7E38E4Q37949656-81D35BFF-6F20-4C63-9EF3-CE8152522847Q38191192-DEB830DA-F30C-4199-91D5-A5057DA73C7EQ38217755-50EEFC26-9D07-4733-B32D-A6F00DF40427Q38269052-499FBE98-1F97-4E2B-9492-2F237BB29518Q38325919-1506F280-C5BA-4A74-9271-737ED26D4B5AQ38570060-05E1968A-572D-402C-8565-B3DD2BC1EDB1Q38680112-F334BE14-767A-4FD1-AB21-0A5CBA40777CQ38749008-0D9497F4-2E60-451A-86F1-051869AEA66FQ38799393-0056443D-10A9-41A0-95D2-30AC40B292FCQ38804579-9BE872A9-F3F7-4091-A6A4-5F158FCAFB27Q38836199-F7F344E5-8FEE-4D83-9FFA-D051BCBC5EB2Q39198686-C1D0A789-1501-41A3-B7FA-48CD6ED3326CQ47997829-94E3E8AC-F5C3-4007-95B1-ADCA91919CBDQ49096230-FC090016-C53E-4964-9A01-8593B6A9CA54Q50089488-33EEF4CA-83EA-4024-B8D7-565AE44CA9E1Q51304386-5C93D22F-15DF-4A09-9581-7DDACF45E165Q52536468-DE69F063-D1D7-42FA-9FE6-DBCAFE7FF10BQ53004635-9E455A9D-3A4E-4757-B598-FFB5B0A54C50
P2860
The cardiovascular physiology and pharmacology of endothelin-1.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The cardiovascular physiology and pharmacology of endothelin-1.
@en
type
label
The cardiovascular physiology and pharmacology of endothelin-1.
@en
prefLabel
The cardiovascular physiology and pharmacology of endothelin-1.
@en
P2860
P1476
The cardiovascular physiology and pharmacology of endothelin-1
@en
P2093
Martine Clozel
P2860
P356
10.1016/B978-0-12-385061-4.00001-5
P50
P577
2010-01-01T00:00:00Z